Literature DB >> 22820531

Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles.

Dan Peer1.   

Abstract

Lipid-based nanoparticles (LNPs) such as liposomes, micelles, and hybrid systems (e.g. lipid-polymer) are prominent delivery vehicles that already made an impact on the lives of millions around the globe. A common denominator of all these LNP-based platforms is to deliver drugs into specific tissues or cells in a pathological setting with minimal adverse effects on bystander cells. All these platforms must be compatible to the physiological environment and prevent undesirable interactions with the immune system. Avoiding immune stimulation or suppression is an important consideration when developing new strategies in drug and gene delivery, whereas in adjuvants for vaccine therapies, immune activation is desired. Therefore, profound understanding of how LNPs elicit immune responses is essential for the optimization of these systems for various biomedical applications. Herein, I describe general concepts of the immune system and the interaction of subsets of leukocytes with LNPs. Finally, I detail the different immune toxicities reported and propose ways to manipulate leukocytes' functions using LNPs.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820531     DOI: 10.1016/j.addr.2012.06.013

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  20 in total

Review 1.  "Eat me" imaging and therapy.

Authors:  Vaishali Bagalkot; Jeffrey A Deiuliis; Sanjay Rajagopalan; Andrei Maiseyeu
Journal:  Adv Drug Deliv Rev       Date:  2016-01-27       Impact factor: 15.470

2.  Toxicity profiling of several common RNAi-based nanomedicines: a comparative study.

Authors:  Dalit Landesman-Milo; Dan Peer
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

Review 3.  Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening.

Authors:  Michael A Bruckman; Xin Yu; Nicole F Steinmetz
Journal:  Nanotechnology       Date:  2013-10-24       Impact factor: 3.874

4.  Charge-Conversion Strategies for Nucleic Acid Delivery.

Authors:  Kingshuk Dutta; Ritam Das; Jewel Medeiros; Pintu Kanjilal; S Thayumanavan
Journal:  Adv Funct Mater       Date:  2021-03-31       Impact factor: 19.924

5.  Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy.

Authors:  Blanka Sharma; Chiranjeevi Peetla; Isaac M Adjei; Vinod Labhasetwar
Journal:  Cancer Lett       Date:  2013-03-21       Impact factor: 8.679

Review 6.  Modulation of Immune Response Using Engineered Nanoparticle Surfaces.

Authors:  Daniel F Moyano; Yuanchang Liu; Dan Peer; Vincent M Rotello
Journal:  Small       Date:  2015-11-30       Impact factor: 13.281

Review 7.  Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles.

Authors:  Jeremy P Bost; Hanna Barriga; Margaret N Holme; Audrey Gallud; Marco Maugeri; Dhanu Gupta; Taavi Lehto; Hadi Valadi; Elin K Esbjörner; Molly M Stevens; Samir El-Andaloussi
Journal:  ACS Nano       Date:  2021-09-10       Impact factor: 15.881

Review 8.  microRNA therapies in cancer.

Authors:  Sacha I Rothschild
Journal:  Mol Cell Ther       Date:  2014-03-04

Review 9.  Harnessing RNAi nanomedicine for precision therapy.

Authors:  Dan Peer
Journal:  Mol Cell Ther       Date:  2014-02-05

Review 10.  Nanoparticles for imaging, sensing, and therapeutic intervention.

Authors:  Lara K Bogart; Genevieve Pourroy; Catherine J Murphy; Victor Puntes; Teresa Pellegrino; Daniel Rosenblum; Dan Peer; Raphaël Lévy
Journal:  ACS Nano       Date:  2014-03-18       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.